medigraphic.com
ISSN 1561-3119 (Electronic)

2013, Number 3

<< Back Next >>

Rev Cubana Pediatr 2013; 85 (3)

Assessment of the health status of patients with phenylketonuria

Álvarez PO, Galcerán CG, de Zayas GT, Velasco PDY, Martínez RR, Ochoa RTZ

Language: Spanish
References: 17
Page:
PDF size: 94.79 Kb.


ABSTRACT

Introduction: phenylketonuria is the most recognized congenital metabolic error. Its early detection and low phwnylalanine diet can prevent mental retardation in these patients.
Objective: to evaluate the impact of the early phenylketonuria prevention program in Holguin province from January 1986 to October 2012.
Methods: a retrospective descriptive study was made in children who were assisted at the phenylketonuria department of pediatric hospital in Holguin province. The universe of study was 12 patients diagnosed with phenylketonuria. The medical histories provided the necessary information. The metabolic control was evaluated through the serum phanylalanin figures recorded in the medical history, the nutritional status was assessed according to the percentile rates set in Cuba and the intellect coefficient was analyzed with psychometric tests.
Results: in this group, 66.6 % (8 patients) presented good metabolic control and 58.3 % (7) showed normal intellect. Of the patients diagnosed with the disease before 1986, three (42.9 %) suffered mild mental retardation and two (28.6 %) were disabled. All the patients diagnosed by this program showed normal intellect and 5 had no symptoms. Four were studying for 80 %. Of the studied patients, 83.3 % (10) were eutrophic.
Conclusions: the early diagnosis program has allowed the significant improvement of the health status of the phenylketonuric patients, with stable metabolic control and noticeable integration to the society.


REFERENCES

  1. Rezvani I, Berhman RE, Kliegman RM, Jonson HB. Nelson ED. Tratado de Pediatría. 18 ed. Amsterdan: Editorial Elsevier; 2009. p. 413-9.

  2. Borrajo E, Esteban I, Hierro FR. Alteraciones del metabolismo de la fenilalanina. En: Cruz M, Jiménez R. Tratado de Pediatría. 7ma. ed. Barcelona: Editorial Ciencias Médicas; 2006. p. 747-9.

  3. Martínez L. Las hiperfenilalaninemias. Recomendaciones para el genetista clínico. La Habana: Editorial Ciencias Médicas; 2006. p. 10-3.

  4. Abadie V, Berthelot J, Feillet F, Maurin N, Mercier A, Ogier de Baulny H. Management of phenylketonuria and hyperphenylalaninemia: the French guidelines. Archives of Pediatrics & Adolescent Medicine. 2005;12(5):594-601.

  5. Faulkner W, Aguiar SA. Métodos seleccionados de análisis clínico. Madrid: Ediciones Juan Bravo; 2007. p. 241-53.

  6. Carrdellá L, Hernández R. Enfermedades moleculares y proteínas de la dieta humana. La Habana: Editorial Ciencias Médicas; 2005. p. 1241-9, 1342-3.

  7. Alonso Álvarez A, Cairo Valcárcel E, Rojas Manresa R. Psicodiagnóstico, pruebas de inteligencia. La Habana: Editorial Ciencias Médicas; 2006. p. 349-60.

  8. Berganza CE, Mezzich JE, Otero Ojeda A, Roberto M. Guía Latinoamericana de Diagnóstico Psiquiátrico (GLADP). Ciudad de México: OPS; 2004. p. 267-74.

  9. Estadísticas del Programa Nacional de Detección Precoz de Hiperfenilalaninemias. Centro Nacional de Genética Médica. Ciudad de la Habana. Cuba; 2006.

  10. Gutiérrez García E, Barrios García B, Toboada Lugo N. Valoración clínica, psicológica y de laboratorio a niños con hiperfenilalaninemias benigna de nacimiento. Rev Cubana Pediatr. 2002;74:4-20.

  11. Rivas Canino MM, Cáceres Diéguez A, Mora Pacheco N, Rivas Campo G. Fenilcetonuria: bases moleculares e implicaciones sociales. MEDISAN [serie en Internet]. 2003 [citado 18 de julio 2012];7(2). Disponible en:http://bvs.sld.cu/revistas/san/vol7_2_03/san12203.htm

  12. Ramalho JR, Ramalho AR, Oliveira CR, Aguiar-Oliveira MH. Evoluçäo do programa de triagem neonatal para o hipotireoidismo congênito e fenilcetonúria no Estado de Sergipe. Arq bras endocrinol metab. 2004;48(6):890-6.

  13. Villaverde R, Escribano JB, Salmeron P, Tortaza D, Mecano J. Diagnóstico tardío de fenilcetonuria como causa de retraso mental en adolescentes. Rev Neurología España. 2005;25(148):1911-6.

  14. Jiménez Soto Z. Metodología de la atención de niños con fenilcetonuria y enfermedad de la orina con olor a miel de arce (EOMA). Arch Lat Americano de Nutrición. 1993;43(3):204-10.

  15. Trefz FK, Scheible D, Frauendienst-Egger G, Korall H, Blau N. Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin. Molecular Genetics and Metabolism. 2005;86:S75-S80.

  16. Brandalize, Salete do Rocio Cavassin. Avaliaçäo de resultados do programa de prevençäo e promoçäo da saúde de fenilcetunúricos do estado do Paraná: condiçäo motora dos portadores de fenilcetunúria com diagnóstico precoce. Arq bras endocrinol metab. 2002;48(6):890-6.

  17. Ferreira Martins F, Barcellos Mendes A, de Souza Cruz WM. Metabolismo do cálcio na fenilcetonúria. Rev Nutr. 2007;22(3):31-7.




2020     |     www.medigraphic.com